NF-kB p65 (RELA) Mouse Monoclonal Antibody [Clone ID: 3D2-4E9-7A8]
CAT#: TA385155
NF-κB p65 (3D2) Mouse monoclonal Antibody
Need it in bulk or conjugated? 
                            Get a free quote
                        
	 热销推荐
热销推荐
CNY 1999.00
CNY 3280.00
货期*
                        2周
                    规格
                        
                         推荐一起购买 (1)
                    
                    
                                        beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
                                    
                                
                                                
                                                
                                                
                                                    CNY 300.00 
                                                    
                                                    CNY 1430.00
                                                
                                            
Specifications
| Product Data | |
| Clone Name | 3D2-4E9-7A8 | 
| Applications | IF, IHC, IP, WB | 
| Recommend Dilution | WB: 1/500-2000 IP: 1/20 ICC: 1/50-1/100 IHC: 1/50-300 | 
| Reactivity | Human, Mouse, Rat | 
| Host | Mouse | 
| Clonality | Monoclonal | 
| Immunogen | Recombinant Protein of Transcription factor p65 | 
| Isotype | IgG1 | 
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.03% Proclin 300, pH 7.3. | 
| Concentration | lot specific | 
| Purification | Affinity Purified | 
| Conjugation | Unconjugated | 
| Storage Condition | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. | 
| Predicted Protein Size | Observed MW (kDa):65 | 
| Gene Name | RELA proto-oncogene, NF-kB subunit | 
| Database Link | |
| Background | Swiss-Prot Acc.Q04206.NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681). | 
| Synonyms | MGC131774; NFKB3; p65 | 
| Reference Data | |
Documents
| Product Manuals | 
| FAQs | 
| SDS | 
Resources
| 抗体相关资料 | 
                         Customer
                                Reviews 
                    
                    
                                Loading...
                            
                        

 
                         
                             
                             
                             
        